Home Tags Antibody-drug Conjugates

Tag: Antibody-drug Conjugates

Antibody-drug conjugates: Recent Advances in Conjugation and Linker Chemistries

Authors: Tsuchikama K , An Z Title: Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Published in: Protein Cell. 2016 Oct 14.Keywords: antibody-drug conjugates; cancer;...
Healthcare And Medicine. Doctor using a digital tablet

Antibody-drug Conjugates and Mechanisms of Resistance

An article published in the December 2016 issue of Molecular Cancer Therapeutics by Frank Loganzo, Matthew Sung and Hans-Peter Gerber, working for Oncology R&D,...

Preclinical Studies Show Significant Improved Therapeutic Index

Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...

EAG Laboratories: Unifying Brands to Leverage Global Contract Research and Testing...

Earlier this week, Evans Analytical Group®, better known as EAG, a global scientific services company offering testing, analysis and characterization to technology- and life-science-related...

Effects of Antibody, Drug and Linker on the Preclinical and Clinical...

Authors: Donaghy H. Title: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates Published in: MAbs. 2016 May-Jun;8(4):659-71. doi: 10.1080/19420862.2016.1156829....

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50...

Pfizer Exercises Options As Part of License Agreement with Philogen

Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products, has confirmed that Pfizer has exercised options granted...

Lonza Expands it’s Mammalian Production Capacity

Over the last decade, biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), therapeutic proteins, immunotherapeutics, and therapeutic (cancer) vaccines have greatly transformed treatment of...

Althea Presents First Phase of its ADC and Cytotoxic Service Offering

Biopharmaceutical contract development and manufacturing services company Ajinomoto Althea recently announced that it is expanding its existing biological drug product manufacturing operations to include highly...

California Life Sciences Association Rewards Sutro Biopharma with Outstanding Partner Award

This week, during the California Life Sciences Association (CLSA) annual Pantheon Ceremony (DiNA Awards), Sutro Biopharma received the Outstanding Partner Award. By giving this award to Sutro, the...